Stage IV or Recurrent Non-small Cell Lung Cancer Study

Phase: 3

Status: Ongoing

About

Phase 2 of a Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)


Details

A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Sponsor: Bristol-Myers Squibb

NCT04623775

Sponsors

HOPE Cancer Center

Hope Cancer Center

Contact

Contact UT Clinical
Scroll to Top